Stock of the Day

CRISPR Therapeutics (CRSP)

$40.70

+$2.13 (+5.5%)

Market Cap: $3.56B

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA.

CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Recent News

• CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript) (seekingalpha.com)
• The Best Stocks to Invest $1,000 in Right Now (fool.com)
• Naimish Patel Sells 3,932 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock (insidertrades.com)